Steffen Klippel

发表

Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis.

H. Heimpel, M. Griesshammer, A. Green, 2003, Blood.

Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera.

M. Lübbert, G. Meinhardt, H. Pahl, 2000, Blood.

PRV-1 mRNA expression discriminates two types of essential thrombocythemia

H. Heimpel, M. Griesshammer, H. Pahl, 2004, Annals of Hematology.

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.

N. Munshi, D. McMillin, P. Richardson, 2007, Hematology/oncology clinics of North America.

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity

K. Anderson, N. Munshi, D. McMillin, 2010, Nature Medicine.

Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells

Christian Steidl, Daniel G Tenen, Frank Rosenbauer, 2006, Nature Genetics.

Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation

K. Anderson, N. Gray, D. McMillin, 2011, PloS one.

In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465

D. McMillin, Jake E. Delmore, P. Richardson, 2009, British journal of haematology.

Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera.

C. Busse, H. Pahl, S. Klippel, 2002, Blood.

Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma

K. Anderson, D. McMillin, Jake E. Delmore, 2011, Haematologica.

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.

Jake E. Delmore, J. Laubach, P. Richardson, 2011, Blood.

Molecular Pathways Induced by Tumor–Microenvironment Interactions in Myeloma and the Regulatory Role of Heat-Shock Proteins

N. Munshi, D. McMillin, Jake E. Delmore, 2009 .

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents

P. Richardson, A. Nagler, C. Mitsiades, 2012, British journal of haematology.

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

Jake E. Delmore, P. Richardson, C. Mitsiades, 2013, Cancer Chemotherapy and Pharmacology.

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

N. Munshi, D. McMillin, J. Laubach, 2009, Seminars in hematology.

Emerging treatments of multiple myeloma; beyond IMIDs and bortezomib

N. Munshi, D. McMillin, J. Laubach, 2009 .

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

N. Munshi, Jake E. Delmore, P. Richardson, 2011 .

In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465

Jake E. Delmore, P. Richardson, N. Mitsiades, 2009, British journal of haematology.

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells

D. McMillin, Jake E. Delmore, J. Laubach, 2012, British journal of haematology.